Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains

Market Focus06-03

On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology sector.

On the news front, the company announced on June 1 a proposed share award plan aimed at improving its incentive mechanism by attracting, motivating, and retaining core employees and service providers. The plan is subject to shareholder approval at the annual general meeting scheduled for June 29. Meanwhile, the company is accelerating commercialization of its core GLP-1 receptor agonist product, which was included in the National Medical Insurance Drug Catalog effective January 1, supporting broader market penetration. Additionally, the company is exploring new application areas including companion animal diabetes and obesity, with related veterinary clinical trial applications formally accepted in early 2026.

Within the Biotechnology sector, the overall sector traded weaker. Among individual stocks, AKESO down 4.79%, 3SBIO down 3.56%, Innovent Bio down 2.98%, BeiGene down 2.90%, SKB Bio down 4.16%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116975222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116975222","market":"us","top_or_hot":-1,"title":"Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains","media":"Market Focus","content":"<p><p>On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology sector.</p><p>On the news front, the company announced on June 1 a proposed share award plan aimed at improving its incentive mechanism by attracting, motivating, and retaining core employees and service providers. The plan is subject to shareholder approval at the annual general meeting scheduled for June 29. Meanwhile, the company is accelerating commercialization of its core GLP-1 receptor agonist product, which was included in the National Medical Insurance Drug Catalog effective January 1, supporting broader market penetration. Additionally, the company is exploring new application areas including companion animal diabetes and obesity, with related veterinary clinical trial applications formally accepted in early 2026.</p><p>Within the Biotechnology sector, the overall sector traded weaker. Among individual stocks, AKESO down 4.79%, 3SBIO down 3.56%, Innovent Bio down 2.98%, BeiGene down 2.90%, SKB Bio down 4.16%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology sector.</p><p>On the news front, the company announced on June 1 a proposed share award plan aimed at improving its incentive mechanism by attracting, motivating, and retaining core employees and service providers. The plan is subject to shareholder approval at the annual general meeting scheduled for June 29. Meanwhile, the company is accelerating commercialization of its core GLP-1 receptor agonist product, which was included in the National Medical Insurance Drug Catalog effective January 1, supporting broader market penetration. Additionally, the company is exploring new application areas including companion animal diabetes and obesity, with related veterinary clinical trial applications formally accepted in early 2026.</p><p>Within the Biotechnology sector, the overall sector traded weaker. Among individual stocks, AKESO down 4.79%, 3SBIO down 3.56%, Innovent Bio down 2.98%, BeiGene down 2.90%, SKB Bio down 4.16%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1116975222","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116975222","pubTimestamp":1780454339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"异动快讯|银诺医药-B常规交易涨10.68%股份奖励计划及商业化加速带动涨势","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology sector.On the news front, the company announced on June 1 a proposed share award plan aimed at improving its incentive mechanism by attracting, motivating, and retaining core employees and service providers. The plan is subject to shareholder approval at the annual general meeting scheduled for June 29. Meanwhile, the company is accelerating commercialization of its core GLP-1 receptor agonist product, which was included in the National Medical Insurance Drug Catalog effective January 1, supporting broader market penetration. Additionally, the company is exploring new application areas including companion animal diabetes and obesity, with related veterinary clinical trial applications formally accepted in early 2026.Within the Biotechnology sector, the overall sector traded weaker. Among individual stocks, AKESO down 4.79%, 3SBIO down 3.56%, Innovent Bio down 2.98%, BeiGene down 2.90%, SKB Bio down 4.16%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116975222","isCrawlerRequest":true}